 |
        |
NewsCanaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More ORTHOCON® Announces Signing of Exclusive, Worldwide License Agreement with Bezwada Biomedical August 31, 2011 - Click to Download ORTHOCON® Receives 510(k) Clearance to Market HEMASORB Apply™ June 1, 2011 - Click to Download ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB® April 21, 2011 - Click to Download ORTHOCON® Announces U.S. Market Launch of HEMASORB® February 17, 2011 - Click to Download ORTHOCON® Names John J. Pacifico President and Chief Executive Officer January 10, 2011- Click to Download |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
Canaan Partners Closes $600 Million Fund, Canaan IX
January 9, 2012 - Click to Read More ORTHOCON® Announces Signing of Exclusive, Worldwide License Agreement with Bezwada Biomedical August 31, 2011 - Click to Download |
||
|
||||||
